Trial Activity Trends
Comparing 2024-2025 vs 2020-2021 trial starts by indication
Rising Indications
+30% or more trial activity growth
Liver Failure Hepatology
'20
'21
'22
'23
'24
'25
'26
+240%
5→17
Obesity Metabolic
'20
'21
'22
'23
'24
'25
'26
+228%
152→499
Stroke Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+208%
92→283
Constipation Gastrointestinal
'20
'21
'22
'23
'24
'25
'26
+191%
11→32
Immune Thrombocytopenia Rare Disease
'20
'21
'22
'23
'24
'25
'26
+151%
37→93
Bipolar Disorder CNS
'20
'21
'22
'23
'24
'25
'26
+136%
14→33
Vitiligo Dermatology
'20
'21
'22
'23
'24
'25
'26
+133%
12→28
Arrhythmia Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+129%
7→16
Hypertrophic Cardiomyopathy Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+114%
7→15
Alopecia Dermatology
'20
'21
'22
'23
'24
'25
'26
+113%
32→68
Lupus Immunology
'20
'21
'22
'23
'24
'25
'26
+106%
140→288
Benign Prostatic Hyperplasia Urology
'20
'21
'22
'23
'24
'25
'26
+100%
10→20
ADHD CNS
'20
'21
'22
'23
'24
'25
'26
+94%
17→33
Epilepsy CNS
'20
'21
'22
'23
'24
'25
'26
+92%
48→92
SCLC Oncology
'20
'21
'22
'23
'24
'25
'26
+91%
91→174
Stable Indications
-30% to +30% change
Ankylosing Spondylitis Immunology
'20
'21
'22
'23
'24
'25
'26
+25%
1716→2145
Solid Tumor (Advanced) Oncology
'20
'21
'22
'23
'24
'25
'26
+27%
1602→2028
Non-Hodgkin Lymphoma Oncology
'20
'21
'22
'23
'24
'25
'26
+16%
935→1088
Breast Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
-4%
913→879
ALL Oncology
'20
'21
'22
'23
'24
'25
'26
-1%
514→511
Prostate Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+8%
453→489
Sarcoma Oncology
'20
'21
'22
'23
'24
'25
'26
-23%
397→304
Lung Cancer (General) Oncology
'20
'21
'22
'23
'24
'25
'26
-27%
398→291
Multiple Myeloma Oncology
'20
'21
'22
'23
'24
'25
'26
+5%
250→263
Hematologic Malignancies Oncology
'20
'21
'22
'23
'24
'25
'26
+5%
253→265
Declining Indications
-30% or more trial activity decline
COVID-19 Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-91%
1955→185
Hepatitis C Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-72%
25→7
Fabry Disease Rare Disease
'20
'21
'22
'23
'24
'25
'26
-50%
6→3
Muscle Spasm Musculoskeletal
'20
'21
'22
'23
'24
'25
'26
-43%
7→4
Merkel Cell Carcinoma Oncology
'20
'21
'22
'23
'24
'25
'26
-41%
32→19
Melanoma Oncology
'20
'21
'22
'23
'24
'25
'26
-36%
404→259
NASH/NAFLD Metabolic
'20
'21
'22
'23
'24
'25
'26
-34%
115→76
Myelofibrosis Oncology
'20
'21
'22
'23
'24
'25
'26
-31%
86→59
Showing top 10 rising and declining trends
Upgrade to Pro for full trend analysis and export capabilities
See Pro FeaturesMethodology: Compares average trial starts in 2024-2025 vs 2020-2021.
Sparklines: Show trial volume 2020→2026 (left to right).